The Evolving Treatment Landscape for Metastatic Castration-Resistant Prostate Cancer

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Nov 15, 2016          Expiration Date: Nov 15, 2017

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.


Click here to download a PDF of the program slides. (Coming soon)

Download (PDF) Click here to download a PDF of the program slides.


Community-based clinicians are challenged to stay up to date with the rapidly diversifying treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). Personalized treatment options are dependent on many factors, including knowledge of prior therapy, presence of resistance markers, bone metastases, and patient preferences. This activity will utilize clinical scenarios to demonstrate how to maximize clinical benefit by incorporating current and emerging data into practice and will provide resources to empower patients in treatment decisions.


Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Co-director, Signal Transduction
Research Program
Yale School of Medicine
New Haven, CT

Read Biography

Oliver Sartor, MD
Medical Director, Tulane Cancer Center
C.E. & Bernadine Laborde Professor for Cancer Research
Department of Medicine and Urology
Tulane Medical School
New Orleans, LA

Read Biography


This activity is intended for community-based urologists, medical oncologists, surgical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment and care of patients with metastatic castration-resistant prostate cancer (mCRPC).

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Review the current and emerging data regarding diagnosis and management of mCRPC
  • Discuss updated guidelines for systemic therapy and survivorship care planning
  • Assess the safety and efficacy data of available therapies and the roles of biomarkers in personalizing the management of mCRPC
  • Empower patients to become active participants in their treatment decisions and health management


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.


The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit . Physicians should claim only the credits commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please email


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Daniel P. Petrylak, MD: Consultant: Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Pfizer, Roche Laboratories, Sanofi Aventis, Tyme Pharmaceuticals; Grant/Research Support: Agenysis, Celgene, Dendron, Eli Lilly, Johnson & Johnson, Millennium, Ocogenix, Progenies, Roche Laboratories, Sanofi Aventis

Oliver Sartor, MD: Consultant: Algela, Amgen, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, Exelixis, GlaxoSmithKline, Johnson & Johnson, Medivation, Oncogenex, Sanofi-Aventis; Grant/Research Support: Algeta, AstraZeneca, Cougar, GlaxoSmithKline, Johnson & Johnson, Sanofi-Aventis

Non-faculty Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Tariqa Ackbarali; Blair St. Amand; Jay Katz, MA, CHCP; Marc Applestein, MD: Nothing to disclose.


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test three times.


Jointly provided by Potomac Center for Medical Education and Rockpointe Oncology




This activity is supported by an independent educational grant from Astellas Pharma Global Development Inc. and Medivation, Inc.

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.